{"filing":{"accession_number":"0001193125-26-254560","cik":"0001590750","ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"d117727d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/d117727d8k.htm"},"events":[{"id":7128,"run_id":6254,"accession_number":"0001193125-26-254560","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure presents the final voting results from Viridian Therapeutics' 2026 Annual Meeting of Stockholders held on June 2, 2026, including election of two Class II directors (Tomas Kiselak and Jennifer K. Moses), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and determination of advisory vote frequency (annually). The tabulated vote counts and board determination constitute a standard shareholder vote results disclosure material to investors' understanding of governance and management approval.","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3926,"accession_number":"0001193125-26-254560","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Viridian Therapeutics' 2026 Annual Meeting of Stockholders held on June 2, 2026, including election of two Class II directors (Tomas Kiselak and Jennifer K. Moses), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and determination of advisory vote frequency (annually). The tabulated vote counts and board determination constitute a standard shareholder vote results disclosure material to investors' understanding of governance and management approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:12.646595+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3926,"accession_number":"0001193125-26-254560","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Viridian Therapeutics' 2026 Annual Meeting of Stockholders held on June 2, 2026, including election of two Class II directors (Tomas Kiselak and Jennifer K. Moses), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and determination of advisory vote frequency (annually). The tabulated vote counts and board determination constitute a standard shareholder vote results disclosure material to investors' understanding of governance and management approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:12.646595+00:00","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-06-03"}]}